Female pattern hair loss (FPHL) is the most common cause of chronic thinning in women, and it is usually diagnosed in the clinic rather than the lab. The workup is less about proving the diagnosis than about two other jobs: grading how far it has progressed, and finding anything that is making it worse, such as low iron, thyroid disease or excess androgens. This guide walks through that workup and then through the trial data for the treatments most often discussed.
Step 1: Recognise the pattern
FPHL typically causes gradual thinning over the crown and mid-scalp with the frontal hairline kept, so the central part looks wider over time. Three distributions are described (Herskovitz and Tosti, Int J Endocrinol Metab 2013):
- Ludwig type: diffuse thinning over the crown with the front preserved.
- Olsen, or "Christmas tree," type: thinning that is widest at the front of the part, forming a triangle that points back.
- Hamilton type: thinning with recession at the temples, closer to the male pattern.
Diffuse shedding that started a few months after an illness, childbirth or a new medicine points more toward telogen effluvium, which often unmasks or overlaps with FPHL. Separating the two is covered in our differential diagnosis guide.
Step 2: Grade the severity
| Scale | Structure | What it is good for | Limitation |
|---|---|---|---|
| Ludwig | 3 grades, from mild crown thinning to extensive loss over the top | Quick shorthand in notes and older studies | Too coarse to show change over a year of treatment |
| Sinclair | 5 points based on the width of the central part | Finer steps; easy to repeat at follow-up | Does not capture frontal accentuation well |
| Savin | A graded series of images of the central part, plus a separate frontal category | Common in clinical trials; shows density as well as part width | Needs the reference images to hand |
Whichever scale is used, the same scale should be used at every visit, alongside photographs of the part taken from the same angle and distance. In the Sinclair spironolactone study discussed below, mid-scalp grade at baseline was the only factor that predicted response, which is a practical reason to grade carefully at the start.
Step 3: Look closely at the scalp
Trichoscopy (scalp dermoscopy) helps confirm FPHL early and distinguish it from other causes. The key finding is variability in hair shaft diameter affecting at least 20% of hairs, together with more fine vellus hairs, both signs of follicle miniaturisation (Herskovitz and Tosti). Dermoscopy can also show features of diffuse alopecia areata, such as tapered fractured hairs, which change the plan entirely (StatPearls, NCBI Bookshelf). A scalp biopsy is usually unnecessary and is kept for cases where the diagnosis remains unclear.
Step 4: Order the right labs, and only those
Most women with FPHL have normal hormone levels and no signs of androgen excess. Testing is therefore split into a baseline set that looks for aggravating factors and an androgen set that is ordered when the history or examination suggests it.
| Test | Why | When it is usually ordered |
|---|---|---|
| Complete blood count and ferritin, with iron studies | Iron deficiency is common and can increase shedding | Most women with thinning or shedding |
| Thyroid function | Both under- and over-active thyroid cause diffuse loss | Most women with thinning or shedding |
| 25-hydroxyvitamin D | Low levels are often corrected as part of general care | Commonly included; evidence of a direct effect on FPHL is mixed |
| Testosterone with SHBG, DHEA, androstenedione and related markers | To detect androgen excess | Irregular periods, acne, hirsutism, infertility or other signs of hyperandrogenism |
| Syphilis serology | A rare mimic of diffuse loss | Only when clinically suspected |
The thyroid, ferritin and vitamin D baseline and the androgen panel above follow the review by Herskovitz and Tosti; StatPearls lists blood count, iron studies and thyroid tests as the core set. Irregular menses, a raised BMI or skin signs of androgen excess should prompt evaluation for polycystic ovary syndrome. How to read ferritin and vitamin D results is covered in our guide to vitamins and hair loss labs.
Step 5: Treatment, and what the trials show
Topical minoxidil
Topical minoxidil remains the approved first-line treatment for women. It needs about 12 months of consistent use before judging, and if it works it is continued, because stopping can trigger a shed (Herskovitz and Tosti). Practical questions about application and early shedding are in our minoxidil FAQ.
Low-dose oral minoxidil
Low-dose oral minoxidil is used off-label, particularly for women who cannot tolerate the topical. In a randomised trial of 52 women with FPHL, 1 mg oral minoxidil daily was compared with 5% topical minoxidil daily for 24 weeks. Hair density rose by 12% with oral and 7.2% with topical treatment; the difference was not statistically significant. Excess facial or body hair occurred in 27% on oral treatment versus 4% on topical, and resting heart rate rose about 10% without tachycardia (Ramos et al., J Am Acad Dermatol).
The largest safety dataset is a retrospective study of 1,404 patients across 10 centres, about 68% of them women. Hypertrichosis was the most frequent effect at 15.1%; lightheadedness (1.7%), fluid retention (1.3%) and tachycardia (0.9%) were uncommon, and 1.2% stopped because of systemic effects (Vañó-Galván et al., J Am Acad Dermatol 2021). Blood pressure, heart disease and pregnancy plans are reviewed before prescribing.
Spironolactone
Spironolactone is an androgen receptor blocker used off-label for FPHL, usually at 50 to 200 mg a day. In an open study of 80 women with biopsy-confirmed FPHL treated for at least 12 months with spironolactone 200 mg or cyproterone acetate, 44% had regrowth, 44% were stable and 12% progressed (Sinclair et al., Br J Dermatol 2005). There was no placebo group, and the authors themselves called for one, since stabilisation alone is hard to judge without knowing the natural course.
Common side effects include menstrual irregularity, dizziness, headache, rash and raised potassium; fewer than 5% of patients stop because of them (StatPearls). In healthy young women taking spironolactone for acne, hyperkalaemia occurred in 0.72% of tests, essentially the background rate (Plovanich et al., JAMA Dermatol 2015). Older women and those with kidney disease or on interacting drugs are a different group and are usually monitored. Spironolactone is not used in pregnancy, so contraception is discussed.
Finasteride and other antiandrogens
Finasteride at 1 mg showed no benefit in a controlled study of postmenopausal women. Small studies used 2.5 to 5 mg, and because it can affect a male fetus, it requires reliable contraception before menopause (Herskovitz and Tosti). Cyproterone acetate is used outside the United States but is not available there.
Treatment evidence at a glance
| Option | Best evidence | Main trade-offs |
|---|---|---|
| Topical minoxidil | Approved; multiple controlled trials | Daily use indefinitely; scalp irritation; initial shed |
| Oral minoxidil 1 mg | One 52-woman RCT vs topical; large safety series | Unwanted hair growth; heart rate; off-label |
| Spironolactone 50 to 200 mg | Open 80-woman study; no placebo trial | Menstrual changes; potassium; not in pregnancy |
| Finasteride | Negative at 1 mg in postmenopausal women; small higher-dose studies | Contraception essential before menopause |
When thinning in a woman needs prompt assessment
- Irregular or absent periods, new acne or coarse facial hair alongside thinning, which can signal androgen excess
- Rapid virilising signs such as voice deepening or temple recession over months, which need urgent hormonal evaluation
- Patches, a smooth shiny scalp, redness or scale around follicles, which suggest alopecia areata or a scarring alopecia rather than FPHL
- Heavy periods with fatigue, which make iron deficiency more likely
- Any plan to start oral minoxidil or spironolactone while pregnant, breastfeeding or trying to conceive